Evidence map›Paper›PMID 39237980›Full record

ArticleJournal of biomedical science2024

Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson's disease models.

Liling Delila, Ouada Nebie, Nhi Thao Ngoc Le, Kelly Timmerman, Deng-Yao Lee, Yu-Wen Wu, Ming-Li Chou, Luc Buée, Szu-Yi Chou, David Blum and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Extracellular Vesicles in Tauopathies: Mechanisms and Applications.International journal of molecular sciences · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Liling DelilaGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0003-4979-3489
Ouada NebieGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0002-6802-4215
Nhi Thao Ngoc LeInternational PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0002-9540-8564
Kelly TimmermanUniv. Lille, Inserm, CHU-Lille, U1172, Lille Neuroscience & Cognition, LiCEND COEN Center, Lille, France.
Deng-Yao LeeGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan.
Yu-Wen WuGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0001-7636-0393
Ming-Li ChouGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0002-6996-5332
Luc BuéeUniv. Lille, Inserm, CHU-Lille, U1172, Lille Neuroscience & Cognition, LiCEND COEN Center, Lille, France.ORCID http://orcid.org/0000-0002-6261-4230
Szu-Yi ChouPh.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institute, Taipei, 11031, Taiwan.ORCID http://orcid.org/0000-0002-4387-749X
David BlumUniv. Lille, Inserm, CHU-Lille, U1172, Lille Neuroscience & Cognition, LiCEND COEN Center, Lille, France.ORCID http://orcid.org/0000-0001-5691-431X
David DevosUniv. Lille, Inserm, CHU-Lille, U1172, Lille Neuroscience & Cognition, LiCEND COEN Center, Lille, France. david.devos@chu-lille.fr.ORCID http://orcid.org/0000-0002-2417-799X
Thierry BurnoufGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, 250 Wu-Xing Street, Taipei, 11031, Taiwan. thburnouf@gmail.com.ORCID http://orcid.org/0000-0002-0507-9243

Funding

National Science and Technology Council 111-2314-B-038-025National Science and Technology Council 112-2811-B-038-048National Science and Technology Council 112-2923-E-038-001
6 · The paper itself

Abstract

backgroundThe burgeoning field of regenerative medicine has significantly advanced with recent findings on biotherapies using human platelet lysates (HPLs), derived from clinical-grade platelet concentrates (PCs), for treating brain disorders. These developments have opened new translational research avenues to explore the neuroprotective effects of platelet-extracellular vesicles (PEVs). Their potential in managing neurodegenerative conditions like traumatic brain injury (TBI) and Parkinson's disease (PD) warrants further exploration. We aimed here to characterize the composition of a PEV preparation isolated from platelet concentrate (PC) supernatant, and determine its neuroprotective potential and neurorestorative effects in cellular and animal models of TBI and PD.

methodsWe isolated PEVs from the supernatant of clinical-grade PC collected from healthy blood donors utilizing high-speed centrifugation. PEVs were characterized by biophysical, biochemical, microscopic, and LC-MS/MS proteomics methods to unveil biological functions. Their functionality was assessed in vitro using SH-SY5Y neuronal cells, LUHMES dopaminergic neurons, and BV-2 microglial cells, and in vivo by intranasal administration in a controlled cortical impact (CCI)-TBI model using 8-weeks-old male C57/BL6 mice, and in a PD model induced by MPTP in 5-month-old male C57/BL6 mice.

resultsPEVs varied in size from 50 to 350 nm, predominantly around 200 nm, with concentrations ranging between 10

conclusionsThe potential of PEV-based therapies in neuroprotection opens new therapeutic avenues for neurodegenerative disorders. The study advocates for clinical trials to establish the efficacy of PEV-based biotherapies in neuroregenerative medicine.

Indexed as

Blood PlateletsBrain Injuries, TraumaticExtracellular VesiclesMice, Inbred C57BLNeuroprotective AgentsParkinson DiseaseAdministration, IntranasalAnimalsDisease Models, AnimalHumansMaleMiceNeuroprotective AgentsBloodCentral Nervous SystemExosomesNeurological disordersNeuroprotection

Identifiers

PMID39237980
PMCPMC11375990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.